ARTA
HTGM

A.R.T. Advisors’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

A.R.T. Advisors’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-116
Closed -$15K – 295
2020
Q2 		$15K Buy
+116
New +$10.2K 0.02% 266
2019
Q4 		– Sell
-123
Closed -$15K – 1841
2019
Q3 		$15K Buy
123
+64
+108% +$12.9K ﹤0.01% 1381
2019
Q2 		$18K Buy
+59
New +$24.6K ﹤0.01% 1300

Other funds holding HTGM

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CPA
Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

A.R.T. Advisors's HTGM Position: Q3 2020 in Review

A.R.T. Advisors sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q3 2020, closing a stake of 116 shares — an estimated $15K sold.

A.R.T. Advisors first reported a position in HTGM in Q2 2019 and held it in 3 quarters. The position peaked at $18K in Q2 2019. 28 funds tracked by Wall St. Rank hold HTGM as of Q3 2020.

  • A.R.T. Advisors reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 116 HTG Molecular Diagnostics, Inc. Common Stock shares in Q3 2020, an estimated $15K.
  • A.R.T. Advisors first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q2 2019 and held it in 3 quarters.
  • A.R.T. Advisors's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $18K in Q2 2019.
  • 28 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q3 2020.

Based on A.R.T. Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.